Recipharm to Lead Kinnovata in Bringing the Clickhaler to China
The Vectura Group’s dry powder inhaler awaits market approval from the Chinese Food and Drug Administration (CFDA, previously known as the SFDA) and Recipharm, who supplies the product in the UK and France, will provide the regulatory body access to its license as part of the process.
Furthermore, the Swedish contract development and manufacturing organization (CDMO) will manufacture the finished product for Tianjin Kinnovata Pharmaceutical Company who signed a joint venture with Vectura in May this year.
Carl-Johan Spak, Executive Vice President, Development & Technology at Recipharm said: “We believe that we can contribute to this, not just from providing access to the product but also from providing services to Kinnovata until its local manufacturing is up and running.”
Recipharm has also said it would be involved in the transfer of manufacturing know-how to Kinnovata’s Chinese facilities.
Containing salbutamol, the Asmasal Clickhaler is used in such conditions as asthma or chronic obstructive pulmonary disease (COPD) in order to open up the airways.
